MX367165B - Formulaciones farmacéuticas para administración subcutánea de furosemida. - Google Patents
Formulaciones farmacéuticas para administración subcutánea de furosemida.Info
- Publication number
- MX367165B MX367165B MX2015014064A MX2015014064A MX367165B MX 367165 B MX367165 B MX 367165B MX 2015014064 A MX2015014064 A MX 2015014064A MX 2015014064 A MX2015014064 A MX 2015014064A MX 367165 B MX367165 B MX 367165B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulations
- furosemide
- subcutaneous administration
- aminomethane
- hydroxymethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361808962P | 2013-04-05 | 2013-04-05 | |
| PCT/US2014/032800 WO2014165660A1 (en) | 2013-04-05 | 2014-04-03 | Pharmaceutical formulations for subcutaneous administration of furosemide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015014064A MX2015014064A (es) | 2017-04-13 |
| MX367165B true MX367165B (es) | 2019-08-07 |
Family
ID=51659206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015014064A MX367165B (es) | 2013-04-05 | 2014-04-03 | Formulaciones farmacéuticas para administración subcutánea de furosemida. |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9884039B2 (enExample) |
| EP (2) | EP2981258B8 (enExample) |
| JP (2) | JP6415535B2 (enExample) |
| KR (2) | KR102493735B1 (enExample) |
| CN (1) | CN105431145B (enExample) |
| AU (1) | AU2014248164B2 (enExample) |
| CA (1) | CA2908935C (enExample) |
| DK (1) | DK2981258T3 (enExample) |
| ES (1) | ES2823589T3 (enExample) |
| IL (1) | IL241917B (enExample) |
| MX (1) | MX367165B (enExample) |
| PT (1) | PT2981258T (enExample) |
| SG (2) | SG10201709388QA (enExample) |
| WO (1) | WO2014165660A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2981258B8 (en) * | 2013-04-05 | 2020-11-11 | scPharmaceuticals Inc. | Pharmaceutical formulations for subcutaneous administration of furosemide |
| DE102014115951A1 (de) * | 2014-11-03 | 2016-05-04 | Merlion Pharmaceuticals Pte Ltd. | Zusammensetzungen, die Finafloxacin und Tris enthalten |
| WO2020120482A1 (en) * | 2018-12-10 | 2020-06-18 | Sq Innovation Ag | Pharmaceutical compositions of furosemide and uses thereof |
| US12397005B2 (en) | 2019-01-04 | 2025-08-26 | Sq Innovation Ag | Pharmaceutical compositions of torsemide and uses thereof |
| CN113271923B (zh) * | 2019-01-04 | 2025-05-13 | Sq创新股份公司 | 呋塞米的药物组合物及其用途 |
| PH12021551811A1 (en) | 2019-01-31 | 2022-03-21 | Scpharmaceuticals Inc | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same |
| CA3190585A1 (en) | 2020-08-05 | 2022-02-10 | Scpharmaceuticals Inc. | Methods of treatment using furosemide |
| CA3215872A1 (en) | 2021-04-02 | 2022-10-06 | Scpharmaceuticals Inc. | Subcutaneous infusion of furosemide |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663348A (en) * | 1985-07-02 | 1987-05-05 | Warner-Lambert Co. | Furosemide salts and pharmaceutical preparations thereof |
| US4698361A (en) * | 1986-05-28 | 1987-10-06 | Schiena Michele G Di | Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same |
| DE3623620A1 (de) * | 1986-07-12 | 1988-01-21 | Boehringer Mannheim Gmbh | Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung |
| CA2109924A1 (en) * | 1991-05-30 | 1992-12-10 | Janina Adamczyk | Reagents containing a nonspecific binding blocker in ion-capture binding assays |
| US5633240A (en) * | 1994-09-01 | 1997-05-27 | Academic Pharmaceuticals | Parenteral solutions containing metolazone |
| IT1283608B1 (it) * | 1996-04-17 | 1998-04-22 | Ricerche Di Schiena Snc Di Dr | Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva. |
| CN1068778C (zh) * | 1998-05-15 | 2001-07-25 | 赵超英 | 救治用的药物组合物及其制备方法 |
| ES2313266T3 (es) | 2005-12-28 | 2009-03-01 | Sensile Pat Ag | Microbomba. |
| WO2008008433A2 (en) | 2006-07-12 | 2008-01-17 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| EP2022518A1 (en) | 2007-08-07 | 2009-02-11 | Sensile Pat AG | Modular drug delivery device for administering discrete doses of a medicament |
| US7923447B2 (en) | 2008-03-17 | 2011-04-12 | Academic Pharmaceuticals Incorporated | Parenteral solutions containing metolazone |
| AR071810A1 (es) | 2008-05-16 | 2010-07-14 | Corthera Inc | Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso. |
| CA2735660C (en) * | 2008-09-09 | 2017-05-30 | Cima Labs Inc. | Dosage forms for weakly ionizable compounds |
| WO2011028997A1 (en) * | 2009-09-04 | 2011-03-10 | Minipumps Llc | Adhesive skin patch with pump for subcutaneous drug delivery |
| BR112014009634A2 (pt) | 2011-10-19 | 2017-05-09 | Mercator Medsystems Inc | preparação e agente terapêutico |
| EP2981258B8 (en) | 2013-04-05 | 2020-11-11 | scPharmaceuticals Inc. | Pharmaceutical formulations for subcutaneous administration of furosemide |
-
2014
- 2014-04-03 EP EP14778339.3A patent/EP2981258B8/en active Active
- 2014-04-03 ES ES14778339T patent/ES2823589T3/es active Active
- 2014-04-03 JP JP2016506607A patent/JP6415535B2/ja active Active
- 2014-04-03 CN CN201480031207.3A patent/CN105431145B/zh active Active
- 2014-04-03 DK DK14778339.3T patent/DK2981258T3/da active
- 2014-04-03 SG SG10201709388QA patent/SG10201709388QA/en unknown
- 2014-04-03 PT PT147783393T patent/PT2981258T/pt unknown
- 2014-04-03 US US14/781,706 patent/US9884039B2/en active Active
- 2014-04-03 MX MX2015014064A patent/MX367165B/es active IP Right Grant
- 2014-04-03 EP EP20189271.8A patent/EP3799869B1/en active Active
- 2014-04-03 KR KR1020217018012A patent/KR102493735B1/ko active Active
- 2014-04-03 CA CA2908935A patent/CA2908935C/en active Active
- 2014-04-03 KR KR1020157031677A patent/KR102266460B1/ko active Active
- 2014-04-03 AU AU2014248164A patent/AU2014248164B2/en active Active
- 2014-04-03 SG SG11201508251RA patent/SG11201508251RA/en unknown
- 2014-04-03 WO PCT/US2014/032800 patent/WO2014165660A1/en not_active Ceased
-
2015
- 2015-10-06 IL IL241917A patent/IL241917B/en active IP Right Grant
-
2018
- 2018-01-23 US US15/877,865 patent/US10272064B2/en active Active
- 2018-10-02 JP JP2018187299A patent/JP6677779B2/ja active Active
-
2019
- 2019-03-07 US US16/295,085 patent/US11433044B2/en active Active
-
2022
- 2022-08-05 US US17/817,729 patent/US12370168B2/en active Active
-
2025
- 2025-07-16 US US19/271,284 patent/US20250339397A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX367165B (es) | Formulaciones farmacéuticas para administración subcutánea de furosemida. | |
| SG10201806539XA (en) | Liquid protein formulations containing ionic liquids | |
| NZ711567A (en) | Antibody formulations | |
| MX2016005395A (es) | Formulacion estable de insulina glulisina. | |
| BR112012018023A2 (pt) | formulações líquidas que contêm anticorpo estabilizado. | |
| MX2014004725A (es) | Formulaciones de etanercept estabilizadas con aminoacidos. | |
| EA201890417A1 (ru) | Генетически кодируемые, внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения | |
| BR112015000203A2 (pt) | formulações de etanercept que exibem redução marcada em partículas sub-visíveis | |
| MX352823B (es) | Formulaciones de proteinas que contienen aminoacidos. | |
| CL2015003738A1 (es) | Formulación líquida estable de amg-416 (velcalcetida) | |
| TN2014000498A1 (en) | Pharmaceutical formulation | |
| IN2014DN08870A (enExample) | ||
| PH12019502645A1 (en) | Non-reversible humidity indicator card | |
| MX2019007608A (es) | Composicion liquida de fibrinogeno humano. | |
| MX369244B (es) | Solucion alcoholica estable de alprostadilo. | |
| MD20170071A2 (ro) | Compoziţii injectabile de paracetamol | |
| MX2016008170A (es) | Proteinas de fusion que comprenden factor ix para tratamiento profilactico de hemofilia y metodos para este. | |
| UA85573U (ru) | Способ нивелирования стресс-индуцированной гипергликемии при острых критических состояниях | |
| MY177091A (en) | Sterically stabilized palmitoleic acid liposome | |
| UA107945U (uk) | Готовий лікарський засіб гіпоамоніємічної дії | |
| IN2013CH01615A (enExample) | ||
| HK1226323A1 (en) | Liquid protein formulations containing ionic liquids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |